|
1
|
Kalantar-Zadeh K, Jafar TH, Nitsch D,
Neuen BL and Perkovic V: Chronic kidney disease. Lancet.
398:786–802. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim X, Ooi L, Ding U, Wu HHL and
Chinnadurai R: Gut Microbiota in patients receiving dialysis: A
review. Pathogens. 13:8012024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Popkov VA, Zharikova AA, Demchenko EA,
Andrianova NV, Zorov DB and Plotnikov EY: Gut Microbiota as a
source of uremic toxins. Int J Mol Sci. 23:4832022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tourountzis T, Lioulios G, Fylaktou A,
Moysidou E, Papagianni A and Stangou M: Microbiome in chronic
kidney disease. Life (Basel). 12:15132022.PubMed/NCBI
|
|
5
|
Evenepoel P, Meijers BK, Bammens BR and
Verbeke K: Uremic toxins originating from colonic microbial
metabolism. Kidney Int Suppl. 114:S12–S19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aronov PA, Luo FJ, Plummer NS, Quan Z,
Holmes S, Hostetter TH and Meyer TW: Colonic contribution to uremic
solutes. J Am Soc Nephrol. 22:1769–1776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan
J, DeSantis TZ, Ni Z, Nguyen TH and Andersen GL: Chronic kidney
disease alters intestinal microbial flora. Kidney Int. 83:308–315.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barreto FC, Barreto DV, Liabeuf S, Meert
N, Glorieux G, Temmar M, Choukroun G, Vanholder R and Massy ZA;
European Uremic Toxin Work Group (EUTox), : Serum indoxyl sulfate
is associated with vascular disease and mortality in chronic kidney
disease patients. Clin J Am Soc Nephrol. 4:1551–1558. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meijers BK, Claes K, Bammens B, de Loor H,
Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y and Evenepoel P:
p-Cresol and cardiovascular risk in mild-to-moderate kidney
disease. Clin J Am Soc Nephrol. 5:1182–1189. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lekawanvijit S, Adrahtas A, Kelly DJ,
Kompa AR, Wang BH and Krum H: Does indoxyl sulfate, a uraemic
toxin, have direct effects on cardiac fibroblasts and myocytes? Eur
Heart J. 31:1771–1779. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meijers BK and Evenepoel P: The gut-kidney
axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression.
Nephrol Dial Transplant. 26:759–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin TY, Wu PH, Lin YT and Hung SC: Gut
dysbiosis and mortality in hemodialysis patients. NPJ Biofilms
Microbiomes. 7:202021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sumida K, Pierre JF, Han Z, Mims TS,
Potukuchi PK, Yuzefpolskaya M, Colombo PC, Demmer RT, Datta S and
Kovesdy CP: Circulating microbial signatures and cardiovascular
death in patients with ESRD. Kidney Int Rep. 6:2617–2628. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Voroneanu L, Burlacu A, Brinza C and Covic
A, Balan GG, Nistor I, Popa C, Hogas S and Covic A: Gut Microbiota
in chronic kidney disease: From composition to modulation towards
better outcomes-a systematic review. J Clin Med. 12:19482023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi X, Gao B, Srivastava A, Izzi Z,
Abdalla Y, Shen W and Raj D: Alterations of gut microbial pathways
and virulence factors in hemodialysis patients. Front Cell Infect
Microbiol. 12:9042842022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kashani K, Cozzolino MG, Massy ZA,
Blankestijn PJ, Stenvinkel P, Rosner MH and Ronco C: Proposal for a
new classification of solutes of interest in uremia and
hemodialysis. Blood Purif. 52:233–241. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo D, Zhao W, Lin Z, Wu J, Lin H, Li Y,
Song J, Zhang J and Peng H: The effects of hemodialysis and
peritoneal dialysis on the gut microbiota of end-stage renal
disease patients, and the relationship between gut microbiota and
patient prognoses. Front Cell Infect Microbiol. 11:5793862021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martín-Del-Campo F, Avesani CM, Stenvinkel
P, Lindholm B, Cueto-Manzano AM and Cortés-Sanabria L: Gut
microbiota disturbances and protein-energy wasting in chronic
kidney disease: A narrative review. J Nephrol. 36:873–883. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bao WH, Yang WL, Su CY, Lu XH, He L and
Zhang AH: Relationship between gut microbiota and vascular
calcification in hemodialysis patients. Ren Fail. 45:21485382023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He L, Yang W, Yang P, Zhang X and Zhang A:
Higher serum trimethylamine-N-oxide levels are associated with
increased abdominal aortic calcification in hemodialysis patients.
Ren Fail. 44:2019–2027. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chaves LD, Abyad S, Honan AM, Bryniarski
MA, McSkimming DI, Stahura CM, Wells SC, Ruszaj DM, Morris ME,
Quigg RJ and Yacoub R: Unconjugated p-cresol activates macrophage
macropinocytosis leading to increased LDL uptake. JCI Insight.
6:e1444102021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koshida T, Gohda T, Sugimoto T, Asahara T,
Asao R, Ohsawa I, Gotoh H, Murakoshi M, Suzuki Y and Yamashiro Y:
Gut Microbiome and Microbiome-derived metabolites in patients with
end-stage kidney disease. Int J Mol Sci. 24:114562023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu J, Li Y, Zhu B, Shen J and Miao L:
Research progress on the kidney-gut-brain axis in brain dysfunction
in maintenance hemodialysis patients. Front Med (Lausanne).
12:15380482025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Davenport A: More frequent hemodialysis
does not effectively clear protein-bound azotemic solutes derived
from gut microbiome metabolism. Kidney Int. 91:1008–1010. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rysz J, Franczyk B, Ławiński J, Olszewski
R, Ciałkowska-Rysz A and Gluba-Brzózka A: The Impact of CKD on
uremic toxins and gut microbiota. Toxins (Basel). 13:2522021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stadlbauer V, Horvath A, Ribitsch W,
Schmerböck B, Schilcher G, Lemesch S, Stiegler P, Rosenkranz AR,
Fickert P and Leber B: Structural and functional differences in gut
microbiome composition in patients undergoing haemodialysis or
peritoneal dialysis. Sci Rep. 7:156012017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen G, Zhang X and Chen F: A
cross-sectional study on gut microbiota in patients with chronic
kidney disease undergoing kidney transplant or hemodialysis. Am J
Transl Res. 15:1756–1765. 2023.PubMed/NCBI
|
|
28
|
Teixeira RR, de Andrade LS, Pereira NBF,
Montenegro H, Hoffmann C and Cuppari L: Gut microbiota profile of
patients on peritoneal dialysis: Comparison with household
contacts. Eur J Clin Nutr. 77:90–97. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Voroneanu L and Covic A, Iliescu S, Baluta
CV, Agavriloaei BD, Stefan AE, Amărandi RM, Văcărean-Trandafir IC,
Ivanov IC and Covic A: Distinct gut microbiome signatures in
hemodialysis and kidney transplant populations. J Clin Med.
14:80322025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fülöp T, Zsom L, Tapolyai MB, Molnar MZ,
Abdul Salim S, Arany I, Hamrahian M and Rosivall L: Peritoneal
dialysis: The unique features by compartmental delivery of renal
replacement therapy. Med Hypotheses. 108:128–132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin TY and Hung SC: Association of
subjective global assessment of nutritional status with gut
microbiota in hemodialysis patients: A case-control study. Nephrol
Dial Transplant. 36:1104–1111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu J, Zhong X, Liu Y, Yan J, Zhou D, Qin
D, Xiao X, Zheng Y, Wen L, Tan R, et al: Correlation between
intestinal flora disruption and protein-energy wasting in patients
with end-stage renal disease. BMC Nephrol. 23:1302022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bi X, Liu Y, Yao L, Ling L, Lu J, Hu C and
Ding W: Gut microbiota dysbiosis and protein energy wasting in
patients on hemodialysis: An observational longitudinal study.
Front Nutr. 10:12706902023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu PH, Liu PY, Chiu YW, Hung WC, Lin YT,
Lin TY, Hung SC, Delicano RA, Kuo MC and Wu CY: Comparative gut
microbiome differences between ferric citrate and calcium carbonate
phosphate binders in patients with End-Stage kidney disease.
Microorganisms. 8:20402020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abdelbary MMH, Kuppe C, Michael SS, Krüger
T, Floege J and Conrads G: Impact of sucroferric oxyhydroxide on
the oral and intestinal microbiome in hemodialysis patients. Sci
Rep. 12:96142022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dai L, Meijers BK, Bammens B, de Loor H,
Schurgers LJ, Qureshi AR, Stenvinkel P and Evenepoel P: Sevelamer
use in End-Stage kidney disease (ESKD) patients associates with
poor vitamin k status and high levels of Gut-derived uremic toxins:
A Drug-bug interaction? Toxins (Basel). 12:3512020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin YT, Lin TY, Hung SC, Liu PY, Wu PH,
Chuang YS, Hung WC, Chiu YW, Kuo MC and Wu CY: Anti-acid drug
treatment induces changes in the gut microbiome composition of
hemodialysis patients. Microorganisms. 9:2862021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin YT, Lin TY, Hung SC, Liu PY, Hung WC,
Tsai WC, Tsai YC, Delicano RA, Chuang YS, Kuo MC, et al:
Differences in the microbial composition of hemodialysis patients
treated with and without β-Blockers. J Pers Med. 11:1982021.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ahmadmehrabi S and Tang WHW:
Hemodialysis-induced cardiovascular disease. Semin Dial.
31:258–267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He H and Xie Y: Effect of different
hemodialysis methods on microbiota in uremic patients. Biomed Res
Int. 2020:67397622020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou J, Yang C, Lei W, Yang Z, Chen J and
Lin H: Exploration of the correlation between intestinal flora and
peritoneal dialysis-related peritonitis. Clin Exp Nephrol.
26:1030–1038. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou J, Yang C, Lei W, Yang Z, Chen J, Lin
H, Li Q and Yuan W: Exploration of the correlation between
intestinal flora and Escherichia coli peritoneal
dialysis-related peritonitis. BMC Nephrol. 23:762022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang L, Zhang H, Su S, Jia Y, Liang C,
Fang Y, Hong D, Li T and Ma F: Risk factor assessment and
microbiome analysis in peritoneal dialysis-related peritonitis
reveal etiological characteristics. Front Immunol. 15:14434682024.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brito JS, Borges NA, Dolenga CJ,
Carraro-Eduardo JC, Nakao LS and Mafra D: Is there a relationship
between tryptophan dietary intake and plasma levels of indoxyl
sulfate in chronic kidney disease patients on hemodialysis? J Bras
Nefrol. 38:396–402. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stockler-Pinto MB, Soulage CO, Borges NA,
Cardozo LFMF, Dolenga CJ, Nakao LS, Pecoits-Filho R, Fouque D and
Mafra D: From bench to the hemodialysis clinic: Protein-bound
uremic toxins modulate NF-κB/Nrf2 expression. Int Urol Nephrol.
50:347–354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang X, Li Y, Yang P, Liu X, Lu L, Chen
Y, Zhong X, Li Z, Liu H, Ou C, et al: Trimethylamine-N-Oxide
promotes vascular calcification through activation of NLRP3
(Nucleotide-Binding domain, leucine-rich-containing family, pyrin
Domain-Containing-3) inflammasome and NF-κB (Nuclear Factor κB)
signals. Arterioscler Thromb Vasc Biol. 40:751–765. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gryp T, Vanholder R, Vaneechoutte M and
Glorieux G: p-Cresyl Sulfate. Toxins (Basel). 9:522017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hu J, Zhong X, Yan J, Zhou D, Qin D, Xiao
X, Zheng Y and Liu Y: High-throughput sequencing analysis of
intestinal flora changes in ESRD and CKD patients. BMC Nephrol.
21:122020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ficek J, Wyskida K, Ficek R, Wajda J,
Klein D, Witkowicz J, Rotkegel S, Spiechowicz-Zatoń U,
Kocemba-Dyczek J, Ciepał J, et al: Relationship between plasma
levels of zonulin, bacterial lipopolysaccharides, D-lactate and
markers of inflammation in haemodialysis patients. Int Urol
Nephrol. 49:717–725. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Engen PA, Dodiya HB, Naqib A, Forsyth CB,
Green SJ, Voigt RM, Kordower JH, Mutlu EA, Shannon KM and
Keshavarzian A: The potential role of Gut-derived inflammation in
multiple system atrophy. J Parkinsons Dis. 7:331–346. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
de Andrade LS, Sardá FAH, Pereira NBF,
Teixeira RR, Rodrigues SD, de Lima JD, Dalboni MA, Aoike DT, Nakao
LS and Cuppari L: Effect of unripe banana flour on Gut-derived
uremic toxins in individuals undergoing peritoneal dialysis: A
randomized, Double-Blind, Placebo-controlled, crossover trial.
Nutrients. 13:6462021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Borges NA, Carmo FL, Stockler-Pinto MB, de
Brito JS, Dolenga CJ, Ferreira DC, Nakao LS, Rosado A, Fouque D and
Mafra D: Probiotic supplementation in chronic kidney disease: A
Double-blind, randomized, placebo-controlled trial. J Ren Nutr.
28:28–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Holle J, Bartolomaeus H, Löber U, Behrens
F, Bartolomaeus TUP, Anandakumar H, Wimmer MI, Vu DL, Kuhring M,
Brüning U, et al: Inflammation in children with CKD linked to gut
dysbiosis and metabolite imbalance. J Am Soc Nephrol. 33:2259–2275.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mafra D, Alvarenga L, F M F Cardozo L,
Schultz J, Rosado AS and Borges NA: Gut microbiota and NLRP3
inflammasome activation in hemodialysis patients: Exploring the
link with systemic inflammation. Mol Biol Rep. 52:4652025.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Samaan E, Eldeeb AA, Ibrahim AB, Erman M,
Sabry AA and Mahmoud MA: Effect of Ramadan fasting on chronic
inflammation markers and gut bacterial endotoxins among Egyptian
hemodialysis patients. Ther Apher Dial. 27:655–660. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo TT, Zhang Z, Sun Y, Zhu RY, Wang FX,
Ma LJ, Jiang L and Liu HD: Neuroprotective effects of sodium
butyrate by restoring gut microbiota and inhibiting TLR4 signaling
in mice with MPTP-Induced Parkinson's disease. Nutrients.
15:9302023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qu Y, An K, Wang D, Yu H, Li J, Min Z,
Xiong Y, Xue Z and Mao Z: Short-Chain fatty acid aggregates
alpha-Synuclein accumulation and neuroinflammation via GPR43-NLRP3
signaling pathway in a model Parkinson's disease. Mol Neurobiol.
62:6612–6625. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu Z, Nie J, Li Y, Huang M, Chen Z, Yu S,
Zheng J, Tan Y and Chen S: Bacteroides coprocola protects
dopaminergic neurons in rotenone-induced Parkinson's disease mouse
model by modulating gut microbiota dysbiosis and inhibiting the
NLRP3 signaling pathway. Transl Neurodegener. 15:72026. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li X, Zheng J, Wang J, Tang X, Zhang F,
Liu S, Liao Y, Chen X, Xie W and Tang Y: Effects of uremic
clearance granules on p38 MAPK/NF-κB signaling pathway, microbial
and metabolic profiles in End-stage renal disease rats receiving
peritoneal dialysis. Drug Des Devel Ther. 16:2529–2544. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang L, Xie F, Tang H, Zhang X, Hu J,
Zhong X, Gong N, Lai Y, Zhou M, Tian J, et al: Gut microbial
metabolite TMAO increases peritoneal inflammation and peritonitis
risk in peritoneal dialysis patients. Transl Res. 240:50–63. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen Y, Liu Y, Wang Y, Chen X, Wang C,
Chen X, Yuan X, Liu L, Yang J and Zhou X: Prevotellaceae produces
butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity
via PPARα-CYP4X1 axis in colonic macrophages. J Exp Clin Cancer
Res. 41:12022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang L, Xu A, Wang J, Fan G, Liu R, Wei L
and Pei M: The effect and mechanism of Fushen Granule on gut
microbiome in the prevention and treatment of chronic renal
failure. Front Cell Infect Microbiol. 13:13342132024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Velasquez MT, Centron P, Barrows I,
Dwivedi R and Raj DS: Gut Microbiota and cardiovascular uremic
toxicities. Toxins (Basel). 10:2872018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kanitsoraphan C, Rattanawong P, Charoensri
S and Senthong V: Trimethylamine N-oxide and risk of cardiovascular
disease and mortality. Curr Nutr Rep. 7:207–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lv Y, Yang X, Sun X and Ren X:
Immune-microbiota dysregulation in maintenance hemodialysis: A 16S
rRNA sequencing-based analysis of gut flora and T cell profiles.
Ren Fail. 47:24986302025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Glorieux G, Gryp T and Perna A:
Gut-derived metabolites and their role in immune dysfunction in
chronic kidney disease. Toxins (Basel). 12:2452020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Al Khodor S and Shatat IF: Gut microbiome
and kidney disease: A bidirectional relationship. Pediatr Nephrol.
32:921–931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Xu P, Zhang M, Cui S, Wang L, Li Y, Li Y
and Jiang C: Gut microbiome and peritoneal inflammation: A new
perspective on peritoneal dialysis-associated peritonitis. Ren
Fail. 47:25425322025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Santhakumaran T, Samad N and Fan SL:
Hydration status measured by BCM: A potential modifiable risk
factor for peritonitis in patients on peritoneal dialysis.
Nephrology (Carlton). 21:404–409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bakinowska E, Olejnik-Wojciechowska J,
Kiełbowski K, Skoryk A and Pawlik A: Pathogenesis of sarcopenia in
chronic kidney Disease-The role of inflammation, metabolic
dysregulation, gut dysbiosis, and microRNA. Int J Mol Sci.
25:84742024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
March DS, Jones AW, Bishop NC and Burton
JO: The efficacy of prebiotic, probiotic, and synbiotic
supplementation in modulating Gut-derived circulatory particles
associated with cardiovascular disease in individuals receiving
dialysis: A systematic review and Meta-analysis of randomized
controlled trials. J Ren Nutr. 30:347–359. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pan Y, Yang L, Dai B, Lin B, Lin S and Lin
E: Effects of probiotics on malnutrition and Health-related quality
of life in patients undergoing peritoneal dialysis: A randomized
controlled trial. J Ren Nutr. 31:199–205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Azamian Y, Abdollahzad H, Rezaeian S,
Rouhani MH and Fatehi MH: The effect of synbiotic supplementation
on plasma levels of advanced glycation end products and
cardiovascular risk factors in hemodialysis patients: A
double-blind clinical trial. Food Sci Nutr. 12:6864–6872. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhu B, Shen J, Jiang R, Jin L, Zhan G, Liu
J, Sha Q, Xu R, Miao L and Yang C: Abnormalities in gut microbiota
and serum metabolites in hemodialysis patients with mild cognitive
decline: A single-center observational study. Psychopharmacology
(Berl). 237:2739–2752. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang J, Wu S, Zhang J, Li Y, Wu Y and Qi
X: Correlation between gut microbiome and cognitive impairment in
patients undergoing peritoneal dialysis. BMC Nephrol. 24:3602023.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shah SN, Knausenberger TB, Pontifex MG,
Connell E, Le Gall G, Hardy TAJ, Randall DW, McCafferty K, Yaqoob
MM, Solito E, et al: Cerebrovascular damage caused by the gut
microbe/host co-metabolite p-cresol sulfate is prevented by
blockade of the EGF receptor. Gut Microbes. 16:24316512024.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Martín-Del-Campo F, Vega-Magaña N,
Salazar-Félix NA, Cueto-Manzano AM, Peña-Rodríguez M,
Cortés-Sanabria L, Romo-Flores ML and Rojas-Campos E: Gut
microbiome is related to cognitive impairment in peritoneal
dialysis patients. Nutrients. 16:26592024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Gao Q, Li D, Wang Y, Zhao C, Li M, Xiao J,
Kang Y, Lin H and Wang N: Analysis of intestinal flora and
cognitive function in maintenance hemodialysis patients using
combined 16S ribosome DNA and shotgun metagenome sequencing. Aging
Clin Exp Res. 36:282024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Soleimani A, Zarrati Mojarrad M, Bahmani
F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P,
Esmaillzadeh A and Asemi Z: Probiotic supplementation in diabetic
hemodialysis patients has beneficial metabolic effects. Kidney Int.
91:435–442. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Borges NA, Stenvinkel P, Bergman P,
Qureshi AR, Lindholm B, Moraes C, Stockler-Pinto MB and Mafra D:
Effects of probiotic supplementation on Trimethylamine-N-Oxide
plasma levels in hemodialysis patients: A pilot study. Probiotics
Antimicrob Proteins. 11:648–654. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lopes RCSO, Theodoro JMV, da Silva BP,
Queiroz VAV, de Castro Moreira ME, Mantovani HC, Hermsdorff HH and
Martino HSD: Synbiotic meal decreases uremic toxins in hemodialysis
individuals: A placebo-controlled trial. Food Res Int. 116:241–248.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Mirzaeian S, Saraf-Bank S, Entezari MH,
Hekmatdoost A, Feizi A and Atapour A: Effects of synbiotic
supplementation on microbiota-derived protein-bound uremic toxins,
systemic inflammation, and biochemical parameters in patients on
hemodialysis: A double-blind, placebo-controlled, randomized
clinical trial. Nutrition. 73:1107132020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhou S, Yan Y, Chu R, Chen N, Wang L,
Zhang H, Wang Y, Wang M, Na L, Ren H, et al: Probiotic treatment
induces changes in intestinal microbiota but does not alter SCFA
levels in peritoneal dialysis patients-a randomized,
placebo-controlled trial. Sci Rep. 14:314132024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang YC, Tsai IJ, Hsieh TH, Wu CC, Lu KC
and Liao MT: Enhanced sleep quality and reduced indoxyl sulfate
levels following probiotic supplementation were linked to gut
microbiota modulation in hemodialysis patients. J Formos Med Assoc.
Aug 27–2025.(Epub ahead of print). doi: 10.1016/j.jfma.2025.08.036.
View Article : Google Scholar
|
|
85
|
Abdelnasier M, Elshinnawy H, Abdelmohsen
WA, Daniel D, Mehanna N and Tohami N: The effect of probiotic use
on gut leakage measured by Zonulin and its relation to P Cresyl
sulfate and inflammation in hemodialysis patients: A prospective
controlled clinical study. Clin Ter. 177:405–413. 2026.PubMed/NCBI
|
|
86
|
Stanford J, Charlton K, Stefoska-Needham
A, Zheng H, Bird L, Borst A, Fuller A and Lambert K: Associations
among plant-Based diet quality, uremic toxins, and gut microbiota
profile in adults undergoing hemodialysis therapy. J Ren Nutr.
31:177–188. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li L, Xiong Q, Zhao J, Lin X, He S, Wu N,
Yao Y, Liang W, Zuo X and Ying C: Inulin-type fructan intervention
restricts the increase in gut microbiome-generated indole in
patients with peritoneal dialysis: A randomized crossover study. Am
J Clin Nutr. 111:1087–1099. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
He S, Xiong Q, Tian C, Li L, Zhao J, Lin
X, Guo X, He Y, Liang W, Zuo X and Ying C: Inulin-type prebiotics
reduce serum uric acid levels via gut microbiota modulation: A
randomized, controlled crossover trial in peritoneal dialysis
patients. Eur J Nutr. 61:665–677. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li L, Zhao J, Wang J, Xiong Q, Lin X, Guo
X, Peng F, Liang W, Zuo X and Ying C: The arsenic-lowering effect
of inulin-type prebiotics in end-stage renal disease: A randomized
crossover trial. Food Funct. 15:355–371. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Esgalhado M, Kemp JA, Azevedo R, Paiva BR,
Stockler-Pinto MB, Dolenga CJ, Borges NA, Nakao LS and Mafra D:
Could resistant starch supplementation improve inflammatory and
oxidative stress biomarkers and uremic toxins levels in
hemodialysis patients? A pilot randomized controlled trial. Food
Funct. 9:6508–6516. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Azevedo R, Esgalhado M, Kemp JA, Regis B,
Cardozo LF, Nakao LS, Brito JS and Mafra D: Resistant starch
supplementation effects on plasma indole 3-acetic acid and aryl
hydrocarbon receptor mRNA expression in hemodialysis patients:
Randomized, double blind and controlled clinical trial. J Bras
Nefrol. 42:273–279. 2020.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
92
|
de Paiva BR, Esgalhado M, Borges NA, Kemp
JA, Alves G, Leite PEC, Macedo R, Cardozo LFMF, de Brito JS and
Mafra D: Resistant starch supplementation attenuates inflammation
in hemodialysis patients: A pilot study. Int Urol Nephrol.
52:549–555. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Baruch EN, Youngster I, Ben-Betzalel G,
Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S,
Bloch N, et al: Fecal microbiota transplant promotes response in
immunotherapy-refractory melanoma patients. Science. 371:602–609.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Davar D, Dzutsev AK, McCulloch JA,
Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding
Q, Pagliano O, et al: Fecal microbiota transplant overcomes
resistance to anti-PD-1 therapy in melanoma patients. Science.
371:595–602. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Scheperjans F, Levo R, Bosch B, Lääperi M,
Pereira PAB, Smolander OP, Aho VTE, Vetkas N, Toivio L, Kainulainen
V, et al: Fecal Microbiota transplantation for treatment of
Parkinson disease: A randomized clinical trial. JAMA Neurol.
81:925–938. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Zhang R, Feng R, Wang J, Chen Y, Liu H,
Zhu Q, Tian H, Qin C, Teng J, Tang B, et al: Gut microbiota
modulation via repeated donor fecal transplantation improves motor
and gastrointestinal symptoms in drug-naïve Parkinson's disease: A
randomized phase 2 trial. Signal Transduct Target Ther. 11:942026.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Samaey A, Vázquez-Castellanos JF,
Caenepeel C, Evenepoel P, Vermeire S, Raes J and Knops N: Effects
of fecal microbiota transplantation for recurrent Clostridium
difficile infection in children on kidney replacement therapy: A
pilot study. Pediatr Nephrol. 39:1201–1212. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Liu J, Ning X, Yuan J, Yu Z, Qin Y, Xing
Y, Zhao J and Sun S: Gut dysbiosis in kidney injury: Therapeutic
potential of fecal microbiota transplantation. Eur J Med Res. Mar
9–2026.(Epub ahead of print). doi: 10.1186/s40001-026-04100-w.
|
|
99
|
Marasco G, Cannarile DC, Cremon C, Papalia
G, Marangoni A, Zucchelli A, Barone M, Lazzarotto T, Brigidi P,
Stanghellini V and Barbara G: Fecal microbiota transplantation for
Clostridioides difficile infection in a peritoneal dialysis
patient: A case report. Perit Dial Int. 45:247–250. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Messaoudene M, Ferreira S, Saint-Lu N,
Ponce M, Truntzer C, Boidot R, Le Bescop C, Loppinet T, Corbel T,
Féger C, et al: The DAV132 colon-targeted adsorbent does not
interfere with plasma concentrations of antibiotics but prevents
antibiotic-related dysbiosis: A randomized phase I trial in healthy
volunteers. Nat Commun. 15:80832024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Rocchetti MT, Cosola C, di Bari I, Magnani
S, Galleggiante V, Scandiffio L, Dalfino G, Netti GS, Atti M,
Corciulo R and Gesualdo L: Efficacy of Divinylbenzenic resin in
removing indoxyl sulfate and P-cresol sulfate in hemodialysis
patients: Results from an in vitro study and an in vivo pilot trial
(xuanro4-Nature 3.2). Toxins (Basel). 12:1702020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Crespo-Salgado J, Vehaskari VM, Stewart T,
Ferris M, Zhang Q, Wang G, Blanchard EE, Taylor CM, Kallash M,
Greenbaum LA and Aviles DH: Intestinal microbiota in pediatric
patients with end stage renal disease: A Midwest Pediatric
Nephrology Consortium study. Microbiome. 4:502016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Li Y, Su X, Zhang L, Liu Y, Shi M, Lv C,
Gao Y, Xu D and Wang Z: Dysbiosis of the gut microbiome is
associated with CKD5 and correlated with clinical indices of the
disease: A case-controlled study. J Transl Med. 17:2282019.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhang P, Wang X, Li S, Cao X, Zou J, Fang
Y, Shi Y, Xiang F, Shen B, Li Y, et al: Metagenome-wide analysis
uncovers gut microbial signatures and implicates taxon-specific
functions in end-stage renal disease. Genome Biol. 24:2262023.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Qin Y, Zhao J, Wang L, Yang X, Wang J, Li
S, Chen Y, Guo J, Wang F and Luo K: Decrease in
Escherichia-Shigella in the gut microbiota of ESKD patients
undergoing maintenance hemodialysis. BMC Nephrol. 26:982025.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Krukowski H, Valkenburg S, Vich Vila A,
Maciel LF, Vázquez-Castellanos JF, Gryp T, Joossens M, Van Biesen
W, Verbeke F, Derrien M, et al: Host factors dictate gut microbiome
alterations in chronic kidney disease more strongly than kidney
function. Nat Microbiol. 11:664–677. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Li R, Zeng L, Xie S, Chen J, Yu Y and
Zhong L: Targeted metabolomics study of serum bile acid profile in
patients with end-stage renal disease undergoing hemodialysis.
PeerJ. 7:e71452019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Bao M, Zhang P, Guo S, Zou J, Ji J, Ding X
and Yu X: Altered gut microbiota and gut-derived p-cresyl sulfate
serum levels in peritoneal dialysis patients. Front Cell Infect
Microbiol. 12:6396242022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
James P, Stanford J, Dixit OVA, Nicdao MA,
McWhinney B, Sud K, Ryan M, Read S, Ahlenstiel G, Lambert K, et al:
Associations between uraemic toxins and gut microbiota in adults
initiating peritoneal dialysis. Toxins (Basel). 17:3342025.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Manokasemsan W, Jariyasopit N,
Wanichthanarak K, Poungsombat P, Kurilung A, Limjiasahapong S,
Thapa K, Sirivatanauksorn Y, Raksasuk S, Srithongkul T, et al:
LC-MS/MS identifies elevated imidazole propionate and gut-derived
metabolite alterations in peritoneal dialysis patients. Comput
Struct Biotechnol J. 27:5271–5280. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kuo TH, Wu PH, Liu PY, Chuang YS, Tai CJ,
Kuo MC, Chiu YW and Lin YT: Identification of gut microbiome
signatures associated with serotonin pathway in tryptophan
metabolism of patients undergoing hemodialysis. Int J Mol Sci.
26:104632025. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Li J, Xing H, Lin W, Yu H, Yang B, Jiang
C, Zhang J, Wu R, Ding F, Pei M and Yang H: Specific gut microbiome
and metabolome changes in patients with continuous ambulatory
peritoneal dialysis and comparison between patients with different
dialysis vintages. Front Med (Lausanne). 10:13023522024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Araujo R, Merino-Ribas A, Pereira L,
Campos J, Silva N, Alencastre IS, Pestana M and Sampaio-Maia B: The
urogenital microbiome in chronic kidney disease patients on
peritoneal dialysis. Nefrologia (Engl Ed). 44:194–203. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wu IW, Lin CY, Chang LC, Lee CC, Chiu CY,
Hsu HJ, Sun CY, Chen YC, Kuo YL, Yang CW, et al: Gut microbiota as
diagnostic tools for mirroring disease progression and circulating
nephrotoxin levels in chronic kidney disease: Discovery and
validation study. Int J Biol Sci. 16:420–434. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zhou Q, Zhang H, Yin L, Li G, Liang W and
Chen G: Characterization of the gut microbiota in hemodialysis
patients with sarcopenia. Int Urol Nephrol. 54:1899–1906. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Tang J and Zhang H, Yin L, Zhou Q and
Zhang H: The gut microbiota from maintenance hemodialysis patients
with sarcopenia influences muscle function in mice. Front Cell
Infect Microbiol. 13:12259912023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang X, Yao S, Yang X, Li Y, Yu Z, Huang J
and Wang J: Peritoneal dialysis promotes microbial-driven
biosynthesis pathways of sesquiterpenes and triterpenes compounds
in end-stage renal disease patients. BMC Microbiol. 24:3772024.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Mortelé O, Iturrospe E, Breynaert A,
Verdickt E, Xavier BB, Lammens C, Malhotra-Kumar S, Jorens PG,
Pieters L, van Nuijs ALN and Hermans N: Optimization of an in vitro
gut microbiome biotransformation platform with chlorogenic acid as
model compound: From fecal sample to biotransformation product
identification. J Pharm Biomed Anal. 175:1127682019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Lockwood MB, Fischer MJ, Silva K,
Contreras BN, Zamora G, Goldstein A, Meinel M, Holden C, Lash J,
Steffens A and Doorenbos A: Acceptability and feasibility of fecal
microBIOME and serum metabolite sample collection in people with
end-stage kidney disease and pain being treated with HemoDialysis:
A pilot study (BIOME-HDp). Contemp Clin Trials Commun.
29:1009952022. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wu IW, Chang LC, Wu YL, Yang HY, Twu YC,
Tsai PY, Paulus S, Resnick R, Chung WH, Yang CW, et al: Gut flora
metagenomic analysis coupled with metabolic and deep immune
profiling in chronic kidney disease. Nephrol Dial Transplant.
39:1333–1343. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Mansour NY, Ismail MF, Sayed NH, El-Ansary
AR and Mohanad M: Serum metabolomics identifies gut-derived uremic
toxins and bile acid dysregulation associated with chronic kidney
disease severity. Sci Rep. 16:123752026. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Liu X, Li Z, Liu H, Xiao M, Zhang X, Deng
Y, Tian B, Sun Y and Xiao X: Diet-microbiota-kidney axis
reprogramming: Mechanistic insights into microbial
metabolite-driven precision nutrition for chronic kidney disease.
Kidney Res Clin Pract. Mar 25–2026.(Epub ahead of print). doi:
10.23876/j.krcp.25.312.
|
|
123
|
Cupisti A, D'Alessandro C, Gesualdo L,
Cosola C, Gallieni M, Egidi MF and Fusaro M: Non-traditional
aspects of renal diets: Focus on fiber, alkali and vitamin K1
intake. Nutrients. 9:4442017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
El Amouri A, Snauwaert E, Foulon A, Vande
Moortel C, Van Dyck M, Van Hoeck K, Godefroid N, Glorieux G, Van
Biesen W, Vande Walle J, et al: Dietary fibre intake is low in
paediatric chronic kidney disease patients but its impact on levels
of gut-derived uraemic toxins remains uncertain. Pediatr Nephrol.
36:1589–1595. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Biruete A, Cross TL, Allen JM, Kistler BM,
de Loor H, Evenepoel P, Fahey GC Jr, Bauer L, Swanson KS and Wilund
KR: Effect of dietary inulin supplementation on the gut microbiota
composition and derived metabolites of individuals undergoing
hemodialysis: A pilot study. J Ren Nutr. 31:512–522. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Esgalhado M, Kemp JA, Paiva BR, Brito JS,
Cardozo LFMF, Azevedo R, Cunha DB, Nakao LS and Mafra D: Resistant
starch type-2 enriched cookies modulate uremic toxins and
inflammation in hemodialysis patients: A randomized, double-blind,
crossover and placebo-controlled trial. Food Funct. 11:2617–2625.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Laffin MR, Tayebi Khosroshahi H, Park H,
Laffin LJ, Madsen K, Kafil HS, Abedi B, Shiralizadeh S and Vaziri
ND: Amylose resistant starch (HAM-RS2) supplementation increases
the proportion of Faecalibacterium bacteria in end-stage renal
disease patients: Microbial analysis from a randomized
placebo-controlled trial. Hemodial Int. 23:343–347. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Fatani AMN, Suh JH, Auger J, Alabasi KM,
Wang Y, Segal MS and Dahl WJ: Pea hull fiber supplementation does
not modulate uremic metabolites in adults receiving hemodialysis: A
randomized, double-blind, controlled trial. Front Nutr.
10:11792952023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Liu S, Liu H, Chen L, Liang SS, Shi K,
Meng W, Xue J, He Q and Jiang H: Effect of probiotics on the
intestinal microbiota of hemodialysis patients: A randomized trial.
Eur J Nutr. 59:3755–3766. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Yang CY, Chen TW, Lu WL, Liang SS, Huang
HD, Tseng CP and Tarng DC: Synbiotics alleviate the gut indole load
and dysbiosis in chronic kidney disease. Cells. 10:1142021.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Climent E, Hevilla F, Padial M,
Barril-Cuadrado G, Blanca M, Jiménez-Salcedo T, López-Picasso M,
Nogueira-Pérez Á and Olveira G: Psychobiotic protection of
nutritional supplements and probiotics in patients undergoing
hemodialysis: A randomized trial. Nutrients. 17:6522025. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Marzocco S, Fazeli G, Di Micco L, Autore
G, Adesso S, Dal Piaz F, Heidland A and Di Iorio B: Supplementation
of short-chain fatty acid, sodium propionate, in patients on
maintenance hemodialysis: Beneficial effects on inflammatory
parameters and gut-derived uremic toxins, a pilot study (PLAN
study). J Clin Med. 7:3152018. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Nazzal L, Roberts J, Singh P, Jhawar S,
Matalon A, Gao Z, Holzman R, Liebes L, Blaser MJ and Lowenstein J:
Microbiome perturbation by oral vancomycin reduces plasma
concentration of two gut-derived uremic solutes, indoxyl sulfate
and p-cresyl sulfate, in end-stage renal disease. Nephrol Dial
Transplant. 32:1809–1817. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Zheng DW, Pan P, Chen KW, Fan JX, Li CX,
Cheng H and Zhang XZ: An orally delivered microbial cocktail for
the removal of nitrogenous metabolic waste in animal models of
kidney failure. Nat Biomed Eng. 4:853–862. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Merino-Ribas A, Araujo R, Bancu I,
Graterol F, Vergara A, Noguera-Julian M, Paredes R, Bonal J and
Sampaio-Maia B: Gut microbiome in hemodialysis patients treated
with calcium acetate or treated with sucroferric oxyhydroxide: A
pilot study. Int Urol Nephrol. 54:2015–2023. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Tang S, Wu G, Liu Y, Xue B, Zhang S, Zhang
W, Jia Y, Xie Q, Liang C, Wang L, et al: Guild-level signature of
gut microbiome for diabetic kidney disease. mBio. 15:e00735242024.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Arteaga-Muller GY, Flores-Treviño S,
Bocanegra-Ibarias P, Robles-Espino D, Garza-González E,
Fabela-Valdez GC and Camacho-Ortiz A: Changes in the progression of
chronic kidney disease in patients undergoing fecal microbiota
transplantation. Nutrients. 16:11092024. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhong HJ, Xie X, Chen WJ, Zhuang YP, Hu X,
Cai YL, Zeng HL, Xiao C, Li Y, Ding Y, et al: Washed microbiota
transplantation improves renal function in patients with renal
dysfunction: A retrospective cohort study. J Transl Med.
21:7402023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Xie W, Yuan J, Feng C, Shi H, Zhang C, Xi
T, Huang J, Fang W, Ni Z, Gu L and Jiang N: Alteration of gut
microbiota contributes to peritoneal fibrosis through increased
production of trimethylamine N-oxide. Gut Microbes. 18:26570482026.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ban Y, Zhang H, Xu Y, Chen F, Wei Q, Wen
X, Yin L, Dong Z, Zhou Q and Ge W: Akkermansia muciniphila
confers renal protection in chronic kidney disease: A multi-omics
mechanistic investigation. BMC Microbiol. 26:3872026. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Mahdavi S: Precision nutritional genomics,
gut microbiota and artificial intelligence in chronic kidney
disease. J Am Nutr Assoc. 45:165–178. 2026.PubMed/NCBI
|
